HC Wainwright Increases Earnings Estimates for Kura Oncology

Kura Oncology, Inc. (NASDAQ:KURA – Free Report) – Stock analysts at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for Kura Oncology in a research report issued on Wednesday, November 11th. HC Wainwright analyst J. Pantginis now forecasts that the company will earn ($3.19) per share for the year, up from their previous forecast of ($3.39). The consensus estimate for Kura Oncology’s current full-year earnings is ($3.21) per share. HC Wainwright also issued estimates for Kura Oncology’s Q4 2026 earnings at ($0.81) EPS, FY2027 earnings at ($2.16) EPS, FY2028 earnings at ($2.05) EPS and FY2029 earnings at ($1.86) EPS.

Several other brokerages also recently weighed in on KURA. Deutsche Bank set a $24.00 price objective on Kura Oncology in a research report on Wednesday, October 14th. Citizens Jmp reiterated a “market outperform” rating and issued a $24.00 target price on shares of Kura Oncology in a research report on Monday, August 24th. Morgan Stanley set a $24.00 target price on Kura Oncology in a research note on Monday, August 24th. Wedbush increased their target price on shares of Kura Oncology from $36.00 to $38.00 and gave the stock an “outperform” rating in a report on Thursday, August 13th. Finally, Raymond James Financial set a $24.00 target price on shares of Kura Oncology in a report on Monday, August 24th. Eleven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $25.88.

Read Our Latest Research Report on KURA

Kura Oncology Price Performance

Kura Oncology stock opened at $7.77 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.71 and a current ratio of 3.60. Kura Oncology has a 52 week low of $6.75 and a 52 week high of $13.90. The stock has a market capitalization of $713.91 million, a P/E ratio of -2.35 and a beta of 0.56. The stock has a fifty day moving average of $10.17 and a 200-day moving average of $9.77.

Kura Oncology (NASDAQ:KURA – Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($0.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.04. Kura Oncology had a negative return on equity of 336.24% and a negative net margin of 369.26%. The firm had revenue of $22.84 million for the quarter, compared to the consensus estimate of $24.94 million.

Hedge Funds Weigh In On Kura Oncology

Several large investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP grew its holdings in Kura Oncology by 32.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,425,945 shares of the company’s stock worth $11,591,000 after acquiring an additional 348,127 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its position in Kura Oncology by 69.7% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 568,845 shares of the company’s stock valued at $6,240,000 after acquiring an additional 233,633 shares during the period. Bank of America Corp DE acquired a new position in Kura Oncology in the 2nd quarter valued at approximately $12,735,000. Great Lakes Advisors LLC bought a new position in shares of Kura Oncology during the second quarter valued at $2,851,000. Finally, Tidal Investments LLC bought a new position in shares of Kura Oncology during the second quarter valued at $1,029,000.

Insider Activity at Kura Oncology

In other news, insider Brian Powl sold 17,020 shares of the stock in a transaction on Monday, September 28th. The stock was sold at an average price of $10.53, for a total value of $179,220.60. Following the completion of the transaction, the insider directly owned 152,249 shares in the company, valued at approximately $1,603,181.97. This represents a 10.06% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Francis Burrows sold 20,726 shares of the stock in a transaction on Thursday, September 24th. The shares were sold at an average price of $10.83, for a total value of $224,462.58. Following the completion of the transaction, the insider owned 42,327 shares of the company’s stock, valued at $458,401.41. The trade was a 32.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 153,881 shares of company stock valued at $1,708,183. 7.60% of the stock is owned by company insiders.

Key Headlines Impacting Kura Oncology

Here are a few of the latest headlines about KURA:

About Kura Oncology

(Get Free Report)

Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its research has centered on therapies that target molecular pathways involved in tumor growth and blood cancers. The company’s best-known program is ziftomenib, an oral menin inhibitor developed for acute myeloid leukemia, including forms associated with NPM1 mutations or KMT2A rearrangements. Kura has also worked on other targeted cancer therapies. Based in San Diego, California, Kura conducts drug development and clinical research in the United States and has worked with international partners to advance its programs.

See Also

Earnings History and Estimates for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.